Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of PRO-231 vs Vigamoxi in Healthy Subjects
NCT06363292Phase 1Completed
- Sponsor
- Laboratorios Sophia
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of PRO-231 in bacterial conjunctivitis (BC) (2 arms), sponsored by Laboratorios Sophia. Primary endpoints: Incidence of Unexpected Adverse Events Related to the Interventions at Day 12, Incidence of Conjunctival Hyperemia and Chemosis at Day 8 and 3 more. Started Jan 2024; status: completed.
02
Drugs
PRO-231
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on NCT06363292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06363292.